Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse

References

• Aarons L, Grennan DM, Siddiqui M. (1983). The binding of ibuprofen to plasma proteins. Eur J Clin Pharmacol 25:815–8.
   PubMed Web of Science ®Google Scholar
• Banker MJ, Clark TH, Williams JA. (2003). Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967–74.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Hoener BA. (2002). Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–21.
   PubMed Web of Science ®Google Scholar
• Bogdan M, Pirnau A, Floare C, Bugeac C. (2008). Binding interaction of indomethacin with human serum albumin. J Pharm Biomed Anal 47:981–4.
   PubMed Web of Science ®Google Scholar
• Brammer KW, Farrow PR, Faulkner JK. (1990). Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12:S318–S26.
   PubMedGoogle Scholar
• Chan KK, Vyas KH, Brandt KD. (1987). In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 76:105–8.
   PubMed Web of Science ®Google Scholar
• Day RO, Francis H, Vial J, et al. (1995). Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol 22:2295–303.
   PubMed Web of Science ®Google Scholar
• Debruyne D. (1997). Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33:52–77.
   PubMed Web of Science ®Google Scholar
• DI L, Breen C, Chambers R, et al. (2017). Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug-drug interaction and related guidelines on highly bound drugs. J Pharm Sci 106:3442–52.
   PubMed Web of Science ®Google Scholar
• EMA. 2012. EMA guidelines on the investigation of drug interactions.
   Google Scholar
• FDA. 2012. FDA Guidance for industry. Drug interaction studies – Study design, data analysis, implications for dosing, and labeling recommendations.
   Google Scholar
• Fuse E, Kuwabara T, Sparreboom A, et al. (2005). Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 45:394–403.
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. (2008). On the rate and extent of drug delivery to the brain. Pharm Res 25:1737–50.
   PubMed Web of Science ®Google Scholar
• Hanke N, Frechen S, Moj D, et al. (2018). PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT Pharmacometrics Syst Pharmacol 7:647–59.
   PubMedGoogle Scholar
• Hasegawa M, Kawai K, Mitsui T, et al. (2011). The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405–10.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Tahara H, Inoue R, et al. (2012). Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. Drug Metab Dispos 40:474–80.
   PubMed Web of Science ®Google Scholar
• Heuberger J, Schmidt S, Derendorf H. (2013). When is protein binding important?. J Pharm Sci 102:3458–67.
   PubMed Web of Science ®Google Scholar
• Hochman J, Tang C, Prueksaritanont T. (2015). Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective. J Pharm Sci 104:916–29.
   PubMed Web of Science ®Google Scholar
• Hoke JF, Dyker AG, Barnaby RJ, Lees KR. (2000). Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke. Eur J Clin Pharmacol 55:867–72.
   PubMed Web of Science ®Google Scholar
• Honda GS, Pearce RG, Pham LL, et al. (2019). Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions. PLoS One 14:e0217564.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, et al. (2009). Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220–7.
   PubMed Web of Science ®Google Scholar
• Kakuni M, Morita M, Matsuo K, et al. (2012). Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett 214:9–18.
   PubMed Web of Science ®Google Scholar
• Kalvass J C, Phipps C, Jenkins G J, et al. (2018). Mathematical and experimental validation of Flux Dialysis Method: an improved approach to measure unbound fraction for compounds with high protein binding and other challenging properties. Drug Metab Dispos 46:458–69.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Nozawa K, et al. (2015). Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers. Drug Metab Dispos 43:309–16.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–10.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2005a). In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 33:754–63.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Okumura H, et al. (2005b). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333–40.
   PubMed Web of Science ®Google Scholar
• Klumpp K, Shimada T, Allweiss L, et al. (2018). Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection. Gastroenterology 154:652–62e8.
   PubMed Web of Science ®Google Scholar
• Lammers I, Lhiaubet-Vallet V, Ariese F, et al. (2013). Binding of naproxen enantiomers to human serum albumin studied by fluorescence and room-temperature phosphorescence. Spectrochim Acta A Mol Biomol Spectrosc 105:67–73.
   PubMed Web of Science ®Google Scholar
• Li F, Zhou D, Guo X. (2003). Study on the protein binding of ketoprofen using capillary electrophoresis frontal analysis compared with liquid chromatography frontal analysis. J Chromatogr Sci 41:137–41.
   PubMed Web of Science ®Google Scholar
• Lin JH. (2008). CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9:46–59.
   PubMed Web of Science ®Google Scholar
• Liu X, Smith BJ, Chen C, et al. (2006). Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443–7.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013a). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 53:178–91.
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013b). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53:167–77.
   PubMed Web of Science ®Google Scholar
• Maurer TS, Debartolo DB, Tess DA, Scott DO. (2005). Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175–81.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, et al. (2017). Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica 47:1052–63.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, et al. (2019). Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver. Xenobiotica 49:1379–87.
   PubMed Web of Science ®Google Scholar
• Mueller H, Wildum S, Luangsay S, et al. (2018). A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol 68:412–20.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ito S, Suzuki M, et al. (2019). Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver. Xenobiotica 49:404–14.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Kamimura H, Suemizu H, et al. (2020). Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. Drug Metabol Pharmacokinet 35:389–96.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Sanoh S, Ohta S. (2018). Chimeric mice with humanized liver: Application in drug metabolism and pharmacokinetics studies for drug discovery. Drug Metab Pharmacokinet 33:31–9.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Sanoh S, Ohta S. (2019). Utility of chimeric mice with humanized liver for predicting human pharmacokinetics in drug discovery: comparison with in vitro-in vivo extrapolation and allometric scaling. Biol Pharm Bull 42:327–36.
   PubMed Web of Science ®Google Scholar
• Nihira K, Nan-Ya KI, Kakuni M, et al. (2019). Chimeric mice with humanized livers demonstrate human-specific hepatotoxicity caused by a therapeutic antibody against TRAIL-receptor 2/death receptor 5. Toxicol Sci 167:190–201.
   PubMed Web of Science ®Google Scholar
• Nishiyama S, Suemizu H, Shibata N, et al. (2015). Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem Res Toxicol 28:2088–90.
   PubMed Web of Science ®Google Scholar
• Papazyan R, Liu X, Liu J, et al. (2018). FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res 59:982–93.
   PubMed Web of Science ®Google Scholar
• Paterson SC, Lim CK, Smith KD. (2003). Analysis of the interaction between alpha-1-acid glycoprotein and tamoxifen and its metabolites. Biomed Chromatogr 17:143–8.
   PubMed Web of Science ®Google Scholar
• Piafsky KM, Borga O. (1977). Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 22:545–9.
   PubMed Web of Science ®Google Scholar
• Redfern WS, Carlsson L, Davis AS, et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45.
   PubMed Web of Science ®Google Scholar
• Sakurama K, Kawai A, Tuan Giam Chuang V, et al. (2018). Analysis of the binding of aripiprazole to human serum albumin: the importance of a chloro-group in the chemical structure. ACS Omega 3:13790–7.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Naritomi Y, Fujimoto M, et al. (2015). Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica 45:605–14.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Nozaki K, Murai H, et al. (2012). Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos 40:76–82.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Tamura Y, Fujino C, et al. (2019). Changes in bile acid concentrations after administration of ketoconazole or rifampicin to chimeric mice with humanized liver. Biol Pharm Bull 42:1366–75.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Yamachika Y, Tamura Y, et al. (2017). Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver. J Toxicol Sci 42:589–96.
   PubMed Web of Science ®Google Scholar
• Scheer N, Wilson ID. (2016). A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discov Today 21:250–63.
   PubMed Web of Science ®Google Scholar
• Schramm P, Wildfeuer A, Sarnow E. (1994). Determination of fluconazole concentrations in the prostatic and seminal vesicle fluid (split ejaculate). Mycoses 37:417–20.
   PubMed Web of Science ®Google Scholar
• Shoda J, Okada K, Inada Y, et al. (2007). Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 37:548–56.
   PubMed Web of Science ®Google Scholar
• Smith DA, DI L, Kerns EH. (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929–39.
   PubMed Web of Science ®Google Scholar
• Smith SA, Waters NJ. (2018). Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein. Pharm Res 36:30.
   PubMed Web of Science ®Google Scholar
• Soars MG, Burchell B, Riley RJ. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382–90.
   PubMed Web of Science ®Google Scholar
• Stangier J, Schmid J, Turck D, et al. (2000). Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 40:1312–22.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Koyama K, Nakai D, et al. (2017). Observation of clinically relevant drug interaction in chimeric mice with humanized livers: the case of valproic acid and carbapenem antibiotics. Eur J Drug Metab Pharmacokinet 42:965–72.
   PubMed Web of Science ®Google Scholar
• Takaoka N, Sanoh S, Okuda K, et al. (2018). Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions. Biochem Pharmacol 154:28–38.
   PubMed Web of Science ®Google Scholar
• Takehara I, Watanabe N, Mori D, et al. (2019). Effect of rifampicin on the plasma concentrations of bile acid-O-sulfates in monkeys and human liver-transplanted chimeric mice with or without bile flow diversion. J Pharm Sci 108:2756–64.
   PubMed Web of Science ®Google Scholar
• Tateno C, Fukumuro M, Masumori S, et al. (2019). Chimeric mice with human hepatocytes: a new system for genotoxicity studies. Mutat Res Genet Toxicol Environ Mutagen 839:9–12.
   PubMed Web of Science ®Google Scholar
• Tateno C, Miya F, Wake K, et al. (2013). Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest 93:54–71.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yamamoto T, Utoh R, et al. (2015). Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-α. Toxicol Pathol 43:233–48.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12.
   PubMed Web of Science ®Google Scholar
• Trainor GL. (2007). The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov 2:51–64.
   PubMed Web of Science ®Google Scholar
• Uchida T, Hiraga N, Imamura M, et al. (2015). Human cytotoxic T lymphocyte-mediated acute liver failure and rescue by immunoglobulin in human hepatocyte transplant TK-NOG Mice. J Virol 89:10087–96.
   PubMed Web of Science ®Google Scholar
• Uchida T, Imamura M, Kan H, et al. (2017). Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology. J Gen Virol 98:1040–7.
   PubMed Web of Science ®Google Scholar
• Uchida M, Tajima Y, Kakuni M, et al. (2018). Organic anion-transporting polypeptide (OATP)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver. Drug Metab Dispos 46:11–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Zrada M, Anderson K, et al. (2014). Understanding and reducing the experimental variability of in vitro plasma protein binding measurements. J Pharm Sci 103:3302–9.
   PubMed Web of Science ®Google Scholar
• Webster R, Leishman D, Walker D. (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5:116–26.
   PubMed Web of Science ®Google Scholar
• Xu D, Michie SA, Zheng M, et al. (2015a). Humanized thymidine kinase-NOG mice can be used to identify drugs that cause animal-specific hepatotoxicity: a case study with furosemide. J Pharmacol Exp Ther 354:73–8.
   PubMed Web of Science ®Google Scholar
• Xu D, Wu M, Nishimura S, et al. (2015b). Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity. J Pharmacol Exp Ther 352:274–80.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Murayama N, et al. (2013). In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol 26:486–9.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Shimizu M, et al. (2012). In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol 25:274–6.
   PubMed Web of Science ®Google Scholar
• Yoshizato K, Tateno C. (2013). A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next?. Expert Opin Drug Metab Toxicol 9:1419–35.
   PubMed Web of Science ®Google Scholar